Company intelligence
Roivant
About Roivant
Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology. The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, pulmonary arterial hypertension, and multiple rare and fatal pediatric conditions. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs. In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.
Verified activity
Signals from Roivant
3 published signals
Research & Knowledge
Roivant reported positive results from the Phase 2 PHocus study of mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), with a -56.3% placebo-adjusted reduction in pulmonary vascular resistance at Week 16.
Reported by Richard Pulik
Research & Knowledge
Roivant initiated the Phase 3 PHrontier study with enrollment underway.
Reported by Richard Pulik
Technology & Infrastructure
Roivant fixed the accounts payable exception problem by cleaning matching logic, restructuring PO reconciliation, and setting tolerances deliberately instead of by accident.
Reported by Mavelyn Cuches, MBA